This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignees: Korea Advanced Institute of Science and Technology, Seoul National University, Yonsei University. Active years: 2013-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:



Years Active: 2013-2016
Title: Eunjoon Kim: Innovator in Genetic Engineering and ADHD Research
Introduction
Eunjoon Kim is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of genetic engineering, particularly in relation to autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). With a total of 2 patents, his work is paving the way for new therapeutic approaches.
Latest Patents
Eunjoon Kim's latest patents include groundbreaking research on genetically engineered models for ASD. One patent focuses on a model carrying a deletion of the Shank2 gene, which results in reduced NMDA receptor function. This model can be utilized to screen candidate therapeutic agents for ASD. Another patent presents a method for using GIT1 knock-out mice as a novel ADHD model. This research allows for the analysis of GIT1 knock-out mice in various biological aspects and provides a screening method for new drugs aimed at treating ADHD.
Career Highlights
Eunjoon Kim has worked at prestigious institutions such as the Korea Advanced Institute of Science and Technology and Yonsei University. His research has garnered attention for its innovative approaches to understanding and treating neurodevelopmental disorders.
Collaborations
Eunjoon Kim has collaborated with notable colleagues, including Eunjin Kim and Min Goo Lee. Their combined expertise contributes to the advancement of research in genetic engineering and behavioral science.
Conclusion
Eunjoon Kim's contributions to genetic engineering and his innovative research on ASD and ADHD are noteworthy. His work continues to influence the scientific community and offers hope for new therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile